Elizabeth Trehu Sells 4,545 Shares of Jounce Therapeutics Inc (JNCE) Stock

Jounce Therapeutics Inc (NASDAQ:JNCE) insider Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $25.06, for a total value of $113,897.70. Following the transaction, the insider now owns 4,545 shares in the company, valued at $113,897.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Elizabeth Trehu also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 5th, Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock. The stock was sold at an average price of $21.50, for a total value of $97,717.50.

Shares of Jounce Therapeutics Inc (JNCE) opened at $27.01 on Tuesday. Jounce Therapeutics Inc has a one year low of $11.05 and a one year high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings data on Thursday, March 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.25. The business had revenue of $13.00 million during the quarter, compared to analyst estimates of $14.95 million. Jounce Therapeutics had a negative return on equity of 10.24% and a negative net margin of 22.76%. The company’s revenue was down 36.0% compared to the same quarter last year. During the same period last year, the company posted $0.05 EPS. research analysts predict that Jounce Therapeutics Inc will post -1.3 EPS for the current year.

JNCE has been the subject of several research reports. Zacks Investment Research lowered Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Robert W. Baird set a $35.00 price objective on Jounce Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. Finally, JPMorgan Chase & Co. set a $28.00 price objective on Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. bought a new stake in shares of Jounce Therapeutics during the 3rd quarter worth $124,000. Rhumbline Advisers bought a new stake in shares of Jounce Therapeutics during the 4th quarter worth $134,000. American International Group Inc. boosted its stake in shares of Jounce Therapeutics by 132.2% during the 3rd quarter. American International Group Inc. now owns 9,559 shares of the company’s stock worth $149,000 after acquiring an additional 5,442 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Jounce Therapeutics by 26.4% during the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after acquiring an additional 2,347 shares in the last quarter. Finally, Ark Investment Management LLC boosted its position in shares of Jounce Therapeutics by 558.9% in the second quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after buying an additional 10,121 shares during the period. 90.81% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Elizabeth Trehu Sells 4,545 Shares of Jounce Therapeutics Inc (JNCE) Stock” was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2018/03/13/elizabeth-trehu-sells-4545-shares-of-jounce-therapeutics-inc-jnce-stock.html.

About Jounce Therapeutics

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply